Why CD38 matters after 42
The mechanism, the research, and an honest account of what is well-established and what is still emerging. You read books with a pen. We wrote this page for that.
1. NAD+ is the molecule you run on
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell. Your mitochondria use it to convert food into usable energy; your brain depends on it for the metabolic work of thinking, focus, and a stable sleep–wake cycle. NAD+ is known to decline with age — that part is not controversial, and most NMN brands stop the story there.
2. CD38 is the enzyme that consumes it
CD38 is a NADase — an enzyme whose activity consumes NAD+. Camacho-Pereira et al. (Cell Metabolism, 2016) identified CD38 as a primary driver of the age-related decline in NAD+, and showed that mice without CD38 maintained more youthful NAD+ levels. CD38 is not a malfunction; it is always present. The question is how active it is.
3. Estrogen kept CD38 in check — until it didn't
For most of a woman's life, estrogen helps keep CD38 activity restrained. As estrogen declines through perimenopause, that restraint loosens, and CD38 activity rises. The Yang lab (Nature Aging, 2024) named CD38 "a key determinant of ovarian aging." Human blood data (Frontiers in Endocrinology, 2022) shows statistically significant NAD+ decline in the 40–49 age cohort specifically.
The plain-language version: NAD+ does not just fade with age in women — in the perimenopausal window it is consumed faster, because the enzyme that consumes it is less restrained.
4. The methylation cost no one mentions
Replenishing NAD+ with a precursor like NMN is sound — but the conversion process spends methyl groups. When methyl-group availability runs low, many people report a heavier, less responsive cognitive state, distinct from hormonal fog. Supporting the methylation process (and, separately, sleep architecture) is why magnesium glycinate is the protocol's third bottle, not an afterthought.
5. So the protocol has three jobs
- ✓ Refill the precursor. NMN at 500 mg — the dose used in human clinical trials of NMN.
- ✓ Slow the eater. Resveratrol and Quercetin are the two most-studied natural CD38 inhibitors in the literature; Quercetin in particular is well characterized (Escande et al., 2013).
- ✓ Cover the cost. Magnesium glycinate supports the methylation load and sleep.
An honest note on the evidence — including label-claim purity
We will not overstate this. The CD38–NAD+–aging chain is well supported in peer-reviewed animal and tissue research. Human NMN trials at this dose range exist. What is not yet confirmed by a single human randomized controlled trial is a precise multiplier for how much faster CD38 accelerates in perimenopausal women specifically — so we never quote one. We describe the mechanism qualitatively, because that is what the evidence currently supports.
Selected references
- • Camacho-Pereira J. et al. "CD38 dictates age-related NAD decline…" Cell Metabolism, 2016. Read it →
- • Yang Q. et al. "NADase CD38 is a key determinant of ovarian aging." Nature Aging, 2024. Read it →
- • "NAD+ decline in women aged 40–49." Frontiers in Endocrinology, 2022. Read it →
- • Escande C. et al. "Flavonoid apigenin / quercetin as CD38 inhibitors." Diabetes, 2013. Read it →
- • NMN label-claim purity replicated in GeroScience, 2024. Read it →
Citations are provided for transparency and do not constitute medical advice. Ember is a dietary supplement; these statements have not been evaluated by the FDA, and this product is not intended to diagnose, treat, cure, or prevent any disease. Consult your provider.
See the protocol →